LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Spine/FDA Clears NuVasive Early-Onset Scoliosis Treatment Implants
Spine

FDA Clears NuVasive Early-Onset Scoliosis Treatment Implants

September 18, 2017 2 min read Premium comments

Advertisement

FDA Clears NuVasive Early-Onset Scoliosis Treatment Implants
MAGEC System / Courtesy of NuVasive, Inc.
Secondary

NuVasive, Inc. has won 510(k) clearance to market a magnetic technology and adjustable growth rods to treat early-onset scoliosis.

Early-onset of scoliosis used to be a sentence of possible endless surgeries to straighten out the spine. Then came growing-rod surgical and genetic solutions to predict curvature growth and apply appropriate interventions. But with 72% of complications in growing-rod surgery for early-onset scoliosis being due to implant related failures, there was room for improvement.

On September 6, 2017, NuVasive, Inc. said the FDA gave the company 510(k) clearance to unite its RELINE­ Small Stature fixation portfolio with the MAGEC System.

Matt Link, the company’s executive vice president of strategy, technology and corporate development stated, “As a low-profile pediatric fixation system, RELINE Small Stature is the first-of-its-kind system to offer competitively-sized pediatric implants that accept up to a 5.0mm rod. The clearance for our redesigned MAGEC system with RELINE Small Stature highlights our speed to market and our further commitment to bringing procedural solutions that transform care to the pediatric deformity market.”

The system is also cost-neutral to traditional growing rod treatment, states the company.

MAGEC

According to the company, the MAGEC system includes redesigned components, which helps provide ease-of-use for the surgeon and help make surgical outcomes more reproducible. The redesign also introduces a 5.0mm rod diameter offering. The company added that patients receive the same benefits found in traditional growing rod treatment with the added benefit of noninvasive distractions. Planned distractions take place in an office setting and are generally quick and painless.

Michael Vitale, M.D., Chief, Pediatric Spine and Scoliosis Surgery at Columbia University said, “With the elimination of additional planned distraction surgeries, the MAGEC system helps simplify care for this patient population like no other technology.”

Advertisement

RELINE

RELINE Small Stature is a comprehensive pediatric deformity fixation system which seeks to achieve optimal construct strength with a reduced implant profile. It is the only small stature system that is compatible with the new 5.0mm MAGEC rod.

Last October, NuVasive said it won expanded FDA clearance for the MAGEC system, indicated for safe use with 1.5 tesla magnetic resonance imaging devices.

NuVasive featured the new combo at the Scoliosis Research Society (SRS) 52nd Annual Meeting & Course held September 6-9, 2017 in Philadelphia, Pennsylvania.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy